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ABSTRACT 41 
Broadly neutralizing antibodies (bnAbs) can prevent lentiviral infection in 42 
non-human primates and may slow the spread of human immunodeficiency virus 43 
type 1 (HIV-1).  Although protection by passive transfer of human bnAbs has been 44 
demonstrated in monkeys, durable expression is essential for its broader use in 45 
humans.  Gene-based expression of bnAbs provides a potential solution to this 46 
problem, though immune responses to the viral vector or to the antibody may limit 47 
its durability and efficacy.  Here, we delivered an adeno-associated viral vector 48 
encoding a simianized form of a CD4bs bnAb, VRC07, and evaluated its 49 
immunogenicity and protective efficacy.  The expressed antibody circulated in 50 
macaques for 16 weeks at levels up to 66 μg/ml, though immune suppression with 51 
cyclosporine A (CsA) was needed to sustain expression.  Gene-delivered simian 52 
VRC07 protected against SHIV infection in monkeys 5.5 weeks after treatment.  53 
Gene transfer of an anti-HIV antibody can therefore protect against infection by 54 
viruses that cause AIDS in primates when the host immune responses are 55 
controlled. 56 
Word Count: 162 57 
IMPORTANCE 58 
Sustained interventions that can prevent HIV-1 infection are needed to halt the 59 
spread of the HIV-1 pandemic.  The protective capacity of anti-HIV antibody gene 60 
therapy has been established in mouse models of HIV-1 infection, but has not been 61 
established for primates.  We show here proof-of-concept that gene transfer of anti-62 
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HIV antibody genes can protect against infection by viruses that cause AIDS in 63 
primates when host immune responses are controlled.  64 
INTRODUCTION 65 
Broadly neutralizing antibodies (bnAbs) arise in HIV-1-infected individuals to 66 
varying degrees (1-3), but vaccination to elicit such antibodies remains a challenge (4-6).  67 
An increasing number of potent bnAbs have been isolated in recent years from HIV-68 
infected individuals (7-12).  These bnAbs represent potential components for passive 69 
immunization in humans based on the finding that they protect non-human primates at 70 
physiologically achievable concentrations (13-16).  71 
The transduction of long-lived cells with a viral vector encoding the heavy and light 72 
chain genes of bnAbs, also known as vectored immunoprophylaxis, aims to protect 73 
against HIV-1 infection by conferring expression of protective antibodies (17-20).  In 74 
particular, viral vectors derived from AAV have yielded sustained expression of multiple 75 
bnAbs in mice (17, 20).  These bnAbs confer neutralizing activity in the plasma of the 76 
mice and thereby protect humanized mice against intraperitoneal, intravenous and 77 
mucosal HIV-1 challenge (20, 21).   78 
Non-human primate models of HIV-1 infection represent the most appropriate model 79 
to assess the ability of antibodies to protect against infection (22-24).  The comparable 80 
physiology of mucosal tissues, their relatively large size, and similar immune system (25) 81 
give non-human primates distinct advantages over humanized mice for assessing the 82 
potential to protect against mucosal transmission of HIV-1 in humans.  However, in the 83 
context of gene delivery, antibody persistence, localization and protection against 84 
mucosal infection has not been well-studied in non-human primates.  A previous study 85 
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conducted in non-human primates advanced this concept using recombinant AAV1 86 
vectors to deliver genes encoding antibody-like molecules called immunoadhesins (26).  87 
The immunoadhesins were expressed for more than one year after gene transfer and 88 
protected most macaques against intravenous simian immunodeficiency virus (SIV) 89 
challenge (26, 27).  It has yet to be shown whether full-length human antibodies 90 
composed of natural heavy and light chains can be delivered through vectored gene 91 
transfer to similarly prevent SHIV infection in non-human primates.  Additionally, 92 
despite being derived from macaque antibody sequence the recombinant immunoadhesins 93 
were immunogenic in 33 % of the macaques expressing them (26).  Later studies have 94 
shown that immunoadhesins possess reduced neutralization activity compared to full-95 
length antibodies (28).  Thus, expression of full-length antibodies in primates remains a 96 
goal for clinical development of vectored immunoprophylaxis.    97 
Long-term functional analysis of human bnAbs in non-human primates can be 98 
complicated by macaque immune responses against the human antibody (29, 30).  In our 99 
previous studies examining durability of protection by antibody protein passive transfer, 100 
we observed macaque responses within weeks against the human antibody in more than 101 
50% of the macaques administered a single 20 mg/kg dose of human VRC01 IgG (31).  102 
The immunogenicity of human proteins in non-human primates is a limitation of this 103 
model system, but it is not predictive or relevant to immunogenicity in humans (30).  The 104 
immunogenicity of human VRC01 was reduced by simianizing the antibody to create a 105 
macaque version of VRC01, which when administered at 20 mg/kg produced no 106 
detectable anti-VRC01 response (31).  Although, AAV8-vectored gene transfer has been 107 
proposed to reduce the immunogenicity of the transgene (32), human proteins such as 108 
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factor IX elicit a humoral response in macaques when delivered by AAV8 vectors (33).  109 
The use of two immunosuppressants, cyclosporine A and rituximab, suppressed the 110 
macaque humoral response targeting factor IX, allowing for the assessment of its 111 
function in macaques (33).  We reasoned that it might be possible to control the 112 
immunogenicity of human antibodies in non-human primates using these above-113 
mentioned approaches, allowing for the examination of protection by AAV8-vectored 114 
bnAb gene transfer.   115 
In this study, we assess the ability of recombinant AAV8 vectors to deliver a 116 
neutralizing antibody to protect against mucosal SHIV-BaLP4 challenge in non-human 117 
primates.  We administered AAV8 vectors encoding a simianized version of the bnAb 118 
VRC07 with and without transient immunosuppressive treatment in rhesus macaques and 119 
demonstrate the efficacy of vectored bnAb immunoprophylaxis to protect against 120 
mucosal SHIV challenge. 121 
MATERIALS AND METHODS 122 
Animals. Indian origin rhesus macaques (Macaca mulatta) weighing between 4 and 10 123 
kilograms were used for non-human primate studies.  The macaques were screened for 124 
AAV8 neutralizing antibodies prior to inclusion into AAV studies. Only macaques with 125 
plasma neutralization ID50 titers less than 1:20 were included.  Macaques enrolled in 126 
SHIV-BaLP4 challenge studies were between 4 and 5 kilograms and subjected to routine 127 
clinical evaluation. C.B-17 SCID mice were purchased from Taconic.  Veterinary 128 
procedures were performed as approved by the Vaccine Research Center Animal Care 129 
and Use Committee.  All animals were housed and cared for in accordance with local, 130 
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state, federal, and institute policies in an American Association for Accreditation of 131 
Laboratory Animal Care (AAALAC)-accredited facility. 132 
 133 
Simianization of VRC07 IgG.  Simianization of VRC07 was performed as previously 134 
described (31).  This process transferred the entire complementarity determining regions 135 
(CDRs) of human VRC07 (huVRC07) onto homologous macaque germline genes that 136 
were chosen based on nucleotide sequence identity (Fig. 1A).  The inferred macaque 137 
homologs were the same as those previously reported for VRC01, since VRC01 and 138 
VRC07 are derived from the same precursor B cell receptor (14, 31, 34). The inferred 139 
macaque variable gene homologs for the heavy and light chain were both 93% identical 140 
to the human germline genes comprising VRC07.  The selected macaque heavy and light 141 
chain J genes were 89 and 95% identical to human germline respectively. Thirteen of the 142 
20 and 11 of the 32 framework region (FWR) somatic mutations from the light chain and 143 
heavy chain of VRC07 respectively were transplanted onto the homologous macaque 144 
germline variable genes (Fig. 1A, B).  These mutations were predicted to be important 145 
based on the crystal structure of VRC07 in complex with gp120 (14, 35), or have been 146 
implicated in correct CDR loop folding (36). In total, the FWRs of the light and heavy 147 
chain variable genes ranged from 78 to 91% and 83 to 100% similar to macaque germline 148 
gene sequence respectively (Fig. 1A).  To generate a full-length simianized 149 
immunoglobulin chain, macaque constant regions were appended after the variable 150 
region of the heavy and light chains.   151 
 152 
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Antibodies.  Antibodies were made by transient transfection of 293F cells using 153 
293fectin transfection reagent (Invitrogen).  Six days after transfection cell culture media 154 
was clarified by centrifugation and filtration through a 0.2 µm filter.  Antibodies were 155 
purified from the cell culture supernatant using a Protein A column on an AKTA FPLC 156 
(GE healthcare).  All purification equipment was pretreated with 1N NaOH prior to use 157 
to eliminate endotoxin contamination.  The purified antibody was dialyzed into 158 
phosphate-buffered saline (PBS) and tested for endotoxin using the LAL assay (Lonza).  159 
Endotoxin above 1 EU per mg of antibody was removed by EndoTrap column 160 
chromatography (Hyglos).   161 
 162 
Quantitative resurfaced HIV core derivative 3 (RSC3) ELISA.  ELISAs were 163 
performed by coating Nunc Maxisorp plates (Thermo Fisher) with 2 μg/mL of RSC3 (9) 164 
overnight at 4 °C.  The ELISA plates were blocked with a 5% skim milk, 2% bovine 165 
serum albumin in Tris-buffered saline-0.05% Tween solution.  To quantify a particular 166 
antibody in the plasma a standard curve was derived by serially diluting purified simian 167 
VRC07 (simVRC07) or human VRC07 (huVRC07) IgG in blocking buffer and adding it 168 
to the ELISA plate.  Heat-inactivated macaque plasma was incubated in the plate for 1 h 169 
at several dilutions.  Pre-immune plasma was used to determine a baseline value for each 170 
macaque and was generally negative.  Pre-immune plasma spiked with known 171 
concentration of huVRC07 or simVRC07 served as positive controls.  Binding of 172 
simVRC07 or huVRC07 was detected with an HRP-linked anti-macaque or anti-human 173 
Fc gamma antibody respectively (Southern Biotech).  The concentration of the VRC07 174 
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antibody in the macaque plasma was calculated based on the standard curve using 175 
Softmax Pro V5.0 software (Molecular Devices).   176 
 177 
Adeno-associated vector preparation.  AAV8 vector was prepared as described 178 
elsewhere with the following modifications (20).  Briefly, 293T cells were transfected 179 
with AAV8 capsid plasmid, transgene plasmid, and pHelp (Applied Viromics) at a 2:4:1 180 
ratio using the Profection kit (Promega).  The cell growth media was replaced with fresh 181 
DMEM (10 % fetal bovine serum and 1% penicillin-streptomycin) 16 h after transfection.  182 
Cell culture supernatant was collected 48, 96, and 120 h post-transfection and filtered 183 
with a 0.45 μm membrane, and stored at 4°C until purification of the vector.  The vector 184 
was precipitated in 8% PEG-8000 and 0.5M NaCl for 2-16 h at 4 °C.  Precipitated vector 185 
was pelleted at 5000 rpm for 30 min at 4 °C and resuspended in 1.37 g/mL ultrapure 186 
cesium chloride (J.T. Baker).  The vector was centrifuged for 24 h at 60000 rpm in quick 187 
seal tubes.  After centrifugation the tubes were punctured and fractionated into a 96 well 188 
plate.  Fractions with a refractive index between 1.3730 and 1.3685 were identified to 189 
contain nearly 90% of the vector.  These fractions were pooled together and subjected to 190 
a second round of cesium chloride density centrifugation using the procedure defined 191 
above.  After the second round of centrifugation the vector was fractionated and pooled 192 
again according to the same refractive index range.  The vector was buffer exchanged 193 
into test formulation buffer 2 (10 mM Tris pH8, 100 mM sodium citrate) and stored at -194 
80 °C.  195 
Vector titer was determined by absolute quantification real time PCR using the 196 
Power SYBR green PCR mix (Invitrogen) and primers pAAVioUBCenhancer_F 197 
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(GCCTTAGAACCCCAGTATCAG) and pAAVioUBCenhancer_R  198 
(ACTTTTCCTCGCCTGTTCCCG).  The standard curve was generated using the 199 
transgene plasmid that was used for vector production.  The vector was treated with 200 
Turbo DNA-free DNAse (Ambion) for 30 min at 37 °C prior to inclusion in real-time 201 
PCR assays to eliminate DNA contamination from the transfection.  Lastly, vector purity 202 
was confirmed by SDS-PAGE and InstaBlue staining.  All vectors prepared for in vivo 203 
administration were examined for endotoxin contamination using the EndoLISA assay 204 
(Hyglos) and were found to be below 1 EU per mg of vector protein. 205 
 206 
In vitro AAV8 neutralization assays.  Twenty thousand 293T cells were plated in a 96-207 
well plate 24 h prior to performing the assay.  Macaque plasma was diluted five fold 208 
starting at a 1:20 dilution.  1×1010 vg of AAV8 encoding luciferase were incubated with 209 
plasma or media for 30 min at 37 °C.  The plasma and vector were then added to the plate 210 
containing the 293T cells.  Forty-eight hours later luciferase was quantified using the 211 
luciferase assay system (Promega) and a Victor3 luminometer (Perkin Elmer).  Percent 212 
neutralization was determined by the following equation: [1-(luciferase expression in the 213 
cultures with plasma/luciferase expression in the cultures without plasma)]×100%.  214 
Percent neutralization curves were plotted in Prism version 6 (GraphPad) and 50% 215 
inhibitory dilutions (ID50) were calculated by fitting a 4-parameter curve. 216 
 217 
Murine AAV gene transfer studies.  The AAV8 vector was diluted up to 100 μL with 218 
PBS.  Four or five week old C.B-17 SCID mice (Taconic) were anesthetized and injected 219 
in the gastrocnemius muscle of each leg with 50 μL of AAV8 vector.  Serum was 220 
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collected from the tail vein of mice and analyzed for VRC07 expression by quantitative 221 
RSC3 ELISA.   222 
 223 
Anti- Furin-2A (F2A) intracellular cytokine staining. Intracellular cytokine staining of 224 
cryopreserved macaque PBMCs was performed as previously described (37). Briefly, the 225 
PBMCs were thawed and rested overnight.  The following day the PBMCs were 226 
stimulated for 6 h with 2 μg/mL of an overlapping pool of F2A peptides in the presence 227 
of 10 μg/mL of Brefeldin A.  PBMCs that underwent the same process but did not 228 
receive the peptide pool served as negative controls and their values were subtracted from 229 
the corresponding treatment wells.  The PBMCs were then stained with a viability dye 230 
and fluorochrome-conjugated antibodies against CD4, CD3, CD8, CD69, IL-2, TNFα, 231 
and IFNγ for analysis on a LSRII flow cytometer (BD Biosciences). Positivity thresholds 232 
for each cytokine were previously determined by the analysis of 100 seronegative 233 
samples. 234 
 235 
Anti-F2A plasma antibody ELISA. ELISA plates were coated with 2 μg/mL of a pool 236 
of synthetic F2A peptides overnight at 4 °C.  The ELISA plates were blocked with a 5% 237 
skim milk, 2% bovine serum albumin in Tris-buffered saline-0.05% Tween solution. 238 
Heat-inactivated macaque plasma was incubated in the plate for 1 h at several dilutions. 239 
Binding of macaque IgG was detected with an HRP-linked anti-macaque Fc gamma 240 
antibody (Southern Biotech) and tetramethylbenzidine substrate (KPL).  The absorbance 241 
at 450 nm in each well was determined with a Spectramax instrument (Molecular 242 
Devices) and Softmax Pro V5.0 software (Molecular Devices).   243 
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 244 
AAV8 vector administration to non-human primates.  On the day of administration 245 
AAV8 vectors were thawed on ice and diluted up to 1 mL in PBS.  Macaques were 246 
anesthetized and a pre-immune blood sample was taken from the femoral vein.  247 
Subsequently, the macaque was administered a single injection of 1 mL of AAV8 vector 248 
in the quadriceps muscle.   249 
  250 
Immune suppression in non-human primates.  At the initiation of the study (day -9) 251 
rhesus macaques were placed under general anesthesia and administered 5 mg/kg of 252 
SANDIMMUNE Injection (Novartis).  SANDIMMUNE Injection was diluted in sterile 253 
PBS and infused intravenously at a rate of 1 mL/min for 60 min.  This procedure was 254 
repeated the following day.  Beginning on day -6 and ending on day 28 macaques were 255 
administered 15-30 mg/kg of SANDIMMUNE oral solution by oral gavage every other 256 
day.  AAV8 encoding simVRC07 IgG was administered on day 0 as stated above.  For 257 
quantification of cyclosporine A blood concentrations, blood was obtained before drug 258 
administration and 1.5-2 h after drug administration.  Cyclosporine A was quantified in 259 
whole blood using the Dimension Systems Cyclosporine A assay (Siemens Diagnostics) 260 
and found to be greater than 1100 ng/mL post-drug administration. 261 
 262 
Mucosal SHIV challenge studies.  Macaques were sedated using general anesthesia and 263 
a pre-challenge blood sample was taken from the femoral vein.  The hindquarters of the 264 
macaque were elevated and 1 mL of SHIV-BaLP4 (12800 TCID50/mL when the titer 265 
was determined in TZM-bl cells; obtained from Norman Letvin) was delivered into the 266 
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rectum (14, 15, 31, 38, 39).  The hindquarters of each macaque were kept elevated for 15 267 
minutes to promote absorption of the inoculum.  To detect infection, plasma viral load 268 
was determined weekly by quantitative PCR.  Specifically, virions were lysed and RNA 269 
was isolated using a QIAsymphony virus/pathogen midi kit (Qiagen).  RNA was reverse 270 
transcribed with Superscript III (Invitrogen).  Viral cDNA was quantified by real-time 271 
PCR in a StepOne PCR (Applied Biosystems) machine using a SIV gag-specific taqman 272 
primer set.  273 
 274 
Monoclonal antibody blocking assays.  ELISA plates were coated with RSC3 and 275 
blocked with ELISA blocking buffer as stated above (9).  0.4 μg/mL of huVRC07 or 276 
simVRC07 was incubated alone or with a 1:20 dilution of either week 0 or week 9 277 
plasma for 30 min at 37 °C. Human VRC03 was used as a negative control antibody and 278 
incubated in the same manner with plasma.  The treated monoclonal antibodies were then 279 
incubated in the RSC3 coated-ELISA plates for 30 min at room temperature.  Binding of 280 
the monoclonal antibody to RSC3 was detected with a HRP-labeled anti-IgG Fc 281 
(Southern Biotech) and developed with a TMB substrate per the manufacturer’s protocol 282 
(KPL).  The absorbance at 450 nm was read and data was analyzed with Softmax Pro 283 
V5.0 software (Molecular Devices). 284 
 285 
Anti-simVRC07 biolayer interferometry binding assays.  A fortéBio Octet Red384 286 
instrument was used to measure binding of plasma to control macaque IgG (NIH NHP 287 
reagent resource) and simVRC07 IgG.  Each antibody (10 μg/ml) was immobilized by 288 
amine coupling to biosensors via activation in an EDC/NHS activation mixture for 300 s 289 
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in 10 mM acetate pH 5.  The biosensor reactivity was quenched using 10 mM 290 
ethanolamine pH 8.5. Typical capture levels were between 0.7 and 1 nm, and variability 291 
within a row of eight tips did not exceed 0.1 nm.  Biosensor tips were then equilibrated 292 
for 300 s in phosphate-buffered saline supplemented with 1 % bovine serum albumin (1 293 
% BSA/PBS) prior to binding measurements.  Plasma samples from macaques were 294 
diluted 1:50 in a 1 % BSA/PBS solution and binding to each immobilized antibody was 295 
assessed for 300 s.  All the assays were performed with agitation set to 1,000 rpm in 1 % 296 
BSA/PBS in order to minimize nonspecific interactions.  The final volume for all of the 297 
solutions was 100 μl/well.  Assays were performed at 30 °C in solid black 96-well plates 298 
(Geiger Bio-One).  299 
 300 
SimVRC07 reverse immunohistochemistry.  Pinch biopsies were taken from the 301 
rectum of rhesus macaques before, and 3 weeks after AAV8 injection.  The biopsies were 302 
fixed for 3h at room temperature in SafeFix II (Fisher Scientific) and washed three times 303 
with 80% ethanol and then stored overnight in 80% ethanol.  The fixed tissues were 304 
paraffin embedded until stained for simVRC07.  Prior to staining for simVRC07, the 305 
tissue was deparaffinized, rehydrated and then blocked with SNIPER (Biocare Medical).  306 
To detect simVRC07 IgG the tissue was incubated with FITC-labeled RSC3, blocked by 307 
hydrogen peroxide, and incubated with anti-FITC-HRP.  The staining was developed 308 
with a DAB peroxidase substrate kit (Biocare Medical), dehydrated and mounted to 309 
slides. 310 
 311 
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In vitro HIV and SHIV neutralization assays.  Monoclonal antibody neutralization of 312 
HIV-1 isolates was assessed in single-cycle pseudovirus assays using TZM-bl cells as 313 
target cells as previously described (40, 41).  Plasma neutralization of replication 314 
competent SHIV-BaLP4 was performed similarly using TZM-bl cells as targets.  Briefly, 315 
macaque plasma was serially diluted in culture media and virus was added to a final 316 
volume of 100 µL.  Virus and plasma were incubated for 30 min at 37 °C then target cells 317 
were added to a final volume of 200 µL.  After 48 h luciferase expression by the TZM-bl 318 
cells was quantified for each well.  Neutralization was quantified as the percent reduction 319 
in luciferase expression in the cultures containing plasma compared to TZM-bl cells 320 
infected in the absence of plasma.  Neutralization curves were fit using a five-parameter 321 
nonlinear regression equation calculated with JMP software (SAS, Cary, NC).  The 322 
neutralization titers were calculated as the concentration of monoclonal antibody or 323 
plasma dilution that inhibited 50% (IC50 or ID50 respectively) of the virus replication 324 
measured in infected cells cultured alone. 325 
 326 
Statistical analyses. Statistical tests were performed using GraphPad Prism version 6.0 327 
(La Jolla, CA). 328 
 329 
RESULTS 330 
Simianization of VRC07 gamma immunoglobulin (IgG). 331 
The human bnAb VRC07 (huVRC07) was simianized to reduce its potential 332 
immunogenicity in macaques (14, 31) (Fig. 1A,B).  We used a CDR grafting procedure 333 
that was previously shown to reduce the immunogenicity of human VRC01 in macaques 334 
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(31).  The simianization procedure yielded variable regions of each antibody chain that 335 
possess macaque framework regions with minimal transplanted huVRC07 residues and 336 
all three huVRC07 CDRs appended to macaque constant regions.  To ensure that the 337 
simianized VRC07 (simVRC07) retained the neutralizing capacity of huVRC07, we 338 
compared its activity in an in vitro TZM-bl pseudovirus assay.  On a panel of 11 clade A, 339 
B, and C HIV-1 isolates simVRC07 showed only a modest reduction in potency (1.8-340 
fold), measured as geometric mean IC50 titer, compared to huVRC07 IgG (Fig. 1C).  We 341 
were thus able to engineer a macaque version of huVRC07 that possessed similar 342 
neutralization activity compared to the wild-type human antibody. 343 
Systemic simVRC07 expression after AAV8 vectored gene transfer 344 
Gene delivery and expression of CD4-like molecules and immunoadhesins has 345 
been previously demonstrated in macaques (26, 42).  However, full-length antibodies 346 
have only been expressed by AAV-mediated gene transfer in mice (17, 18, 20, 43).  To 347 
determine whether full-length antibodies could be expressed in non-human primates after 348 
intramuscular injection of a viral vector, we constructed single-stranded DNA AAV8 349 
vectors encoding either huVRC07 IgG (AAV8-huVRC07) or simVRC07 IgG (AAV8-350 
simVRC07) (18-20).  The transgene cassette utilized the furin-2A antibody expression 351 
system and removed all AAV open reading frames (Fig. 2A).  The inverted terminal 352 
repeats of AAV2 flank each end of the transgene cassette to enable packaging of the 353 
heavy and light chain genes of VRC07 into viral vectors.  The transduction activity of 354 
these vectors was assessed by injecting 2.5×1010 vector genomes (vg) of either vector 355 
intramuscularly into immunodeficient mice.  After vector administration, the serum 356 
concentration of simVRC07 IgG peaked at 377 µg/mL four weeks after vector 357 
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administration, which was higher than the concentration of huVRC07 IgG at the same 358 
time point.  However, over the 9 weeks of follow-up the serum concentrations of 359 
huVRC07 and simVRC07 were both maintained at approximately 200 μg/mL in the mice 360 
(Fig.2B).  These VRC07 concentrations were similar to the values previously published 361 
for VRC01 (20).    362 
 To determine whether an AAV vector could support expression of a transgenic 363 
full-length antibody in primates, 1×1013 vg of AAV8-simVRC07 vector were 364 
administered to each of four rhesus macaques.  After vector administration, we detected 365 
simVRC07 IgG in the plasma of all four macaques within one week (Fig. 2C).  The 366 
plasma concentration of simVRC07 IgG peaked between weeks 2 and 4 in the macaques 367 
at concentrations of 2.5 to 7.7 µg/mL.  However, simVRC07 IgG was undetectable in the 368 
plasma of all macaques by week 9.  Similar expression kinetics were seen when human 369 
VRC07 or simian VRC01 was expressed instead of simVRC07, and when a 10-fold 370 
lower dose of AAV8-simVRC07 vector (1×1012 vg) was administered to macaques (data 371 
not shown).  A single administration of the vector was given in each study because the 372 
macaques seroconverted for AAV8 neutralizing antibodies after vector injection (Table 373 
1).  374 
To determine whether simVRC07 IgG trafficked to gut mucosal surfaces when 375 
delivered by intramuscular AAV8 vector injection, we performed immunohistochemistry 376 
on rectal biopsies using a labeled HIV Env core to detect simVRC07 IgG.  377 
Immunoperoxidase staining of week 3 rectal tissue revealed simVRC07 IgG capable of 378 
binding envelope in the epithelial cells in the crypts and bordering the rectal lumen (Fig. 379 
2D).  This staining was not seen in samples taken prior to treatment (week 0).  The 380 
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presence of simVRC07 IgG at this mucosal site indicated that the antibody produced 381 
from muscle cells trafficked to a mucosal site where it could potentially protect against 382 
virus transmission. 383 
Development of anti-idiotypic antibodies is associated with decreased simVRC07 384 
expression  385 
To determine whether a macaque humoral response to simVRC07 was elicited by 386 
AAV8-simVRC07 administration, we assayed for binding antibodies against simVRC07 387 
IgG. Specific antibodies to simVRC07 arose between 2 and 4 weeks after vector 388 
administration and increased over the 12 weeks of study (Fig. 3A). The magnitude of 389 
these anti-simVRC07 antibodies correlated inversely with the simVRC07 IgG plasma 390 
concentration in the four macaques (Fig. 3B; P <0.0001). As expected, substantial anti-391 
transgene responses were also observed when AAV8-huVRC07 was administered to 392 
macaques (data not shown). 393 
We asked whether these antibodies recognized the simVRC07 antigen binding 394 
site by analyzing whether the macaque plasma could block binding of simVRC07, 395 
huVRC07, or a control CD4 binding site antibody, VRC03, to a resurfaced stabilized core 396 
(RSC) of HIV-1 Env, RSC3 (9).  Before vector administration, no blocking activity was 397 
detectable.  In contrast, plasma from three of the four macaques blocked simVRC07 and 398 
huVRC07 binding to HIV-1 envelope (Fig. 3C). No effect on a divergent CD4bs mAb, 399 
VRC03, was observed, suggesting an anti-idiotypic component.  Plasma from one 400 
macaque inhibited binding by simVRC07 and huVRC07, and to a lesser extent VRC03.  401 
The moderate blocking of VRC03 by this sera was possibly due to recognition of 402 
framework residues shared between all three antibodies, since VRC07 and VRC03 are 403 
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derived from the same VH gene.  The binding of humVRC07 and its ability to block the 404 
interaction with HIV-1 Env indicated that the macaques generated antibodies to the 405 
variable antigen-binding regions of simVRC07 and humVRC07. Therefore in general, the 406 
administration of AAV8-simVRC07 vectors in macaques elicited antibodies targeting the 407 
huVRC07 residues in simVRC07.  408 
Plasma IgG and CD4+ T cells against the furin-2A peptide arise after vector 409 
administration 410 
The furin-2A (F2A) sequence used to separate the heavy and light chain genes 411 
contains the 2A sequence from foot-and-mouth-disease virus and thus could potentially 412 
be immunogenic when expressed in vivo. Although we used an optimized version of the 413 
F2A sequence designed to eliminate this sequence from the antibody (19), it remained 414 
possible that T and B cells could react with the F2A peptide delivered in the AAV8 415 
vector to macaques. For cellular responses, cytokine production by F2A-stimulated CD4 416 
and CD8 T cell responses were assessed in cryopreserved PBMCs before AAV8-417 
simVRC07 delivery and at two time points after vector delivery. None of the four 418 
animals possessed CD8+ T cells that responded to F2A peptide stimulation (Fig. 4A). In 419 
contrast, macaque AZ36 possessed CD4+ T cells after vector administration that 420 
produced IFNγ, TNFα, and IL-2 in response to F2A peptides (Fig. 4B). CD4+ T cells 421 
isolated after AAV8 vector administration from macaque AZ66 were also stimulated by 422 
F2A peptides to produce TNFα and IL-2 (Fig. 4B). These same two monkeys as well as 423 
an additional macaque possessed moderate levels of anti-F2A antibodies, which were not 424 
present 2 weeks after vector administration but were evident by week 8 (Fig. 4C).  425 
 19
Suppression of host immunity increases simVRC07 expression following gene 426 
transfer  427 
 Cross-species immunogenicity limits the persistence of human proteins in non-428 
human primates (30).  Given the high concentrations of simVRC07 expressed by the 429 
same AAV8 vectors in immunodeficient mice, we hypothesized that the vectors could 430 
function similarly in non-human primates in the absence of transgene immunity.  We 431 
therefore attempted to suppress the macaque immune response to the transgene by 432 
administering cyclosporine A (CsA).  This approach was previously found to permit 433 
expression of human factor IX in macaques (33).  CsA was initially administered to six 434 
macaques nine days prior to AAV8-simVRC07 vector administration. The plasma 435 
concentration of simVRC07 IgG increased in the macaques over the first three weeks, 436 
reaching a peak of 66 µg/mL in one macaque and a mean peak plasma concentration of 437 
38.12 µg/mL for all six macaques (Fig. 5A,B).  In one macaque, simVRC07 expression 438 
achieved 41 μg/mL in the plasma, highlighting an initial effect of the treatment, but anti-439 
transgene antibodies rendered simVRC07 undetectable despite ongoing CsA 440 
administration (Fig. 5A).  SimVRC07 expression persisted in the remaining five 441 
macaques during the CsA regimen, and the peak concentrations of simVRC07 were 442 
significantly higher than those observed in macaques not immunosuppressed, although 443 
the macaques were not age and weight-matched between groups (Fig. 5B; Mann-444 
Whitney, P=0.0095).  Immune suppressive treatment was halted 4 weeks after vector 445 
injection to determine whether simVRC07 expression would continue and to assess 446 
whether anti-transgene responses would arise.  The simVRC07 IgG plasma concentration 447 
decreased in all of the animals, however three out of the six macaques maintained 448 
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detectable simVRC07 IgG in the plasma for the following 16 weeks (Fig. 5A).  449 
Examination of transgene-specific antibodies showed that all three macaques in which 450 
simVRC07 diminished to undetectable concentrations possessed anti-transgene 451 
antibodies ( Fig. 5C).  In contrast, the three macaques with detectable circulating 452 
simVRC07 did not generate transgene-specific binding antibodies even after the cessation 453 
of immune suppressive treatment (Fig. 5C).  454 
AAV8-simian VRC07 confers protection against SHIV infection 455 
To determine whether AAV8 transfer of neutralizing antibody genes could protect 456 
macaques from mucosal SHIV infection, the monkeys given CsA and AAV8-simVRC07 457 
were intrarectally challenged with CCR5-tropic SHIV-BaLP4 5.5 weeks after vector 458 
administration. The control group of macaques received a CsA dosing regimen identical 459 
to that of the treatment group, and were administered an AAV8 vector encoding a 460 
simianized non-HIV antibody (AAV8-control IgG) on day 0.  The plasma concentration 461 
of simVRC07 IgG on the day of challenge in the macaques given AAV8-simVRC07 462 
ranged from 0-38.9 µg/mL (Fig. 5A).  Similarly, for the macaques with detectable 463 
simVRC07 the in vitro neutralization titers (ID50) against the challenge stock varied 464 
from 1:31 to 1:1028 (Fig. 6A).  Upon challenge all five macaques given AAV8 encoding 465 
the control IgG became infected (Fig. 6B).  Four out of 6 macaques administered AAV8-466 
simVRC07 resisted infection (Fig. 6B, Fisher’s Exact P=0.0455). Macaque A11E035 had 467 
no detectable simVRC07 in circulation and was expectedly one of the infected animals. 468 
The other infected macaque, A11E045, displayed the lowest peak and day of challenge 469 
concentration of simVRC07 IgG among all of the macaques in the AAV8-simVRC07 470 
group and also showed anti-simVRC07 plasma activity (Fig. 5A, C).  471 
 21
 472 
DISCUSSION 473 
Broad and potent neutralizing antibodies to HIV-1 provide a potential tool to 474 
prevent infection in the absence of an effective vaccine (13).  Because passive infusion of 475 
antibodies requires multiple and sustained treatment, we explored whether HIV-1 bnAb 476 
gene delivery could protect non-human primates from mucosal SHIV infection.  Transfer 477 
of full-length immunoglobulin genes in the absence of immune suppression yielded 478 
antibody concentrations of approximately 5 μg/ml on average in non-human primates, 479 
which was increased to an average of 38 μg/mL when macaques were immune-480 
suppressed at the time of vector delivery.  In a previous study, Johnson et al. injected a 481 
single stranded AAV1 vector encoding a soluble CD4 immunoadhesin and readily 482 
detected significant levels in macaques (26).  In the present study, similar detectable 483 
levels were also reached with an AAV8 expressing full-length IgG, suggesting that AAV-484 
vectored gene delivery in non-human primates is not limited to immunoadhesins.  485 
Johnson and colleagues observed concentrations approaching 200 μg/mL for two other 486 
immunoadhesins in macaques.  These immunoadhesins differed from the CD4 487 
immunoadhesin in that they were derived from natural macaque antibodies and that they 488 
were delivered with self-complementary AAV vectors (26, 44).  It is presently unclear to 489 
what extent each of these differences account for the enhanced expression in macaques.  490 
Similar to the CD4 immunoadhesin, the present study used a single-stranded DNA AAV 491 
vector rather than a self-complementary AAV vector.  The advantages of each vector 492 
format are still debated, particularly in relation to the size of the transgene each encodes 493 
and the expression level each type affords.  494 
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Passive transfer of VRC01 protein suggests that accumulation of antibody in 495 
mucosal tissue improves protection against mucosal SHIV challenge (38).  Mucosal 496 
localization of antibodies produced by gene transfer presumably contributes to protective 497 
efficacy.  Immunohistochemistry of the rectal tissue indicated that simVRC07 IgG 498 
expressed from intramuscular gene delivery localizes to mucosal tissue in a manner 499 
similar to passively transferred bnAb protein (31, 38).  Thus, it seems that once the 500 
transgenic antibody is expressed in vivo, it traffics to the mucosa where it can counteract 501 
virus infection in a manner analogous to passively transferred antibody protein.  502 
Protection against mucosal infection in macaque models of HIV infection has 503 
been demonstrated after passive transfer of monoclonal antibodies (45-48), but it has not 504 
been shown previously after gene transfer of bnAbs.  We show here that gene transfer of 505 
bnAb genes yields sufficient antibody expression in non-human primates to confer 506 
protection.  Previous protein passive transfer studies have shown that the probability of 507 
protection against viral challenge is related to the plasma antibody concentration (14, 49). 508 
In our previous studies with VRC01 and the same SHIV-BaLP4 challenge, we infused 509 
VRC01 at various doses and used a regression analysis to correlate the level of plasma 510 
antibody with in vivo protection (14, 15, 38). These data revealed that 50% protection 511 
was achieved at a plasma VRC01 concentration of  2.54 μg/mL. Monkeys A11E006 and 512 
A11E045 both had plasma concentrations of simian VRC07 in the 1-2 μg/mL range, and 513 
one of the two macaques became infected. This result is consistent with the probability of 514 
protection for VRC01-like antibodies being less than 50% at concentrations below 2.54 515 
μg/mL (14, 15, 38).  516 
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The macaques in this study were treated with CsA prior to SHIV-BaLP4 517 
challenge.  Cyclosporine A has been shown to inhibit SIV and HIV-1 replication in vitro 518 
(50-52).  However, inhibitory effects of cyclosporine A were not a factor for our 519 
challenge as these macaques were challenged 11 days after the cessation of CsA 520 
treatment (5.5 weeks after AAV injection), and all macaques given control AAV8 vectors 521 
after cyclosporine A treatment became infected (Fig. 6B). 522 
Inhibitory antibodies developed against the transgenic antibody simVRC07 in 523 
macaques in this current study, despite our efforts to simianize the antibody.  In our 524 
previous protein passive transfer study, human VRC01 was immunogenic in two 525 
macaques given a single 20 mg/kg dose, but simian VRC01 was not (31).  The 526 
development of antibodies against simVRC07 was not entirely unexpected as it contains 527 
all three huVRC07 CDRs in their entirety and 24 human residues within its framework 528 
regions. The development of antibodies against huVRC07 in humans would be 529 
unexpected, as most human antibodies when delivered by protein passive transfer are not 530 
immunogenic (53).  However, for comparison to our previous studies with simian 531 
VRC01, we passively transferred 5 mg/kg of simian VRC07 protein into two macaques 532 
and did not observe any detectable anti-simian VRC07 plasma antibody responses.  533 
Therefore, passive transfer of antibody protein may not be predictive of immunogenicity 534 
of AAV-delivered antibodies. Though we generally have observed more anti-antibody 535 
responses after administration of vector rather than protein, we cannot currently draw 536 
definitive conclusions about the relative immunogenicity of each modality.  Future 537 
studies will help to define the relative contribution of each modality. Vectored gene 538 
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delivery of a human antibody in humans has yet to be reported, therefore it remains to be 539 
determined whether anti-transgene antibodies will be observed.  540 
The anti-transgene antibodies observed here were inhibitory but more importantly 541 
were correlated inversely with simVRC07 plasma levels (Fig. 3B).  This inverse 542 
correlation suggested that these antibodies were binding to circulating simVRC07 IgG in 543 
the macaque and contributed to its clearance.  Thus, anti-transgene antibodies are one 544 
factor that is predictive of the failure of AAV-vectored antibody gene transfer.  We show 545 
here that transient immunosuppressive monotherapy is sufficient to increase the longevity 546 
of transgene expression in most cases.  These results corroborate previous studies that 547 
used immune suppression to eliminate anti-factor IX antibodies in canines and macaques 548 
(33, 54).  Reduction of transgene immunogenicity has also been achieved by reducing the 549 
vector dose at single or multiple injection sites (54-56).  It is possible that the two doses 550 
tested here were still above the threshold for reducing transgene immunogenicity, and 551 
that administering a very low dose of vector may still reduce transgene immunogenicity.  552 
However, lowering the dose of vector to prevent transgene immunogenicity will have to 553 
be balanced with the need to generate protective concentrations of the transgenic 554 
antibody.   555 
The molecular mechanisms that resulted in persistent expression of the HIV-1 556 
bnAb in non-human primates after cessation of immune suppression are presently 557 
unclear.  One hypothesis is the induction of immune tolerance to the transgenic antibody.  558 
B cells attempting to respond to simVRC07 during immune suppression would not 559 
receive the T cell help that is required according to the two–signal activation model (57).  560 
These B cells would subsequently be clonally deleted or rendered anergic reducing the 561 
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anti-transgene humoral response once immune suppression is halted.  Alternatively, the 562 
antigen persistence model could explain the induction of tolerance in our system (58).  563 
According to this model the persistence of simVRC07 in secondary lymphoid organs 564 
over the four-week immunosuppression period would lead to tolerance that prevents the 565 
development of anti-simVRC07 antibodies after withdrawal of immune suppression.  566 
The global health community awaits a protective intervention to curb the spread 567 
of the HIV-1 pandemic in at-risk populations.  AAV-vectored bnAb gene transfer can 568 
protect humanized mice from HIV-1 infection and may be able to similarly create a 569 
sustained protective barrier in humans.  In support of this notion, we show here that gene 570 
transfer of a bnAb can protect macaques from mucosal SHIV infection more than one 571 
month after vector delivery.  These results extend the protective efficacy seen previously 572 
in humanized mice (21) to SHIV infection in NHP and provides support for further 573 
investigation in humans.  574 
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 826 
FIGURE LEGENDS 827 
Figure 1.  The design of simian VRC07 IgG.  (A) Amino acid alignment of huVRC07 and 828 
simVRC07 heavy and light chain variable regions. Residues that are identical to the inferred 829 
germline gene (mac gl) shown across the top are denoted as periods. The complementarity 830 
determining regions residues (CDRs; red) and grafted framework residues (FWRs; green) are 831 
shown.  The huVRC07 CDR3 is shown attached to the germline sequence since the original 832 
sequences after recombination could not be predicted with a high degree of certainty.  833 
Somatic mutations in the FWRs that were not grafted to make simVRC07 are highlighted in 834 
blue. The percent similarity of each segment of simVRC07 compared to the macaque 835 
germline is denoted above the sequences.  The number of grafted residues is shown in 836 
parentheses above each segment.  (B) The tertiary sequence location of amino acids selected 837 
for engraftment onto the macaque germline gene. Somatic mutations in the FWRs of the 838 
heavy chain (HC) and light chain (LC) of huVRC07 are shown as spheres on the crystal 839 
structure (14).  The CDRs (red) and somatic mutations in the FWRs (blue or green) are 840 
colored to correspond to the alignment above and are depicted in proximity to HIV-1 gp120 841 
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(gray).  (C) Comparison of HIV-1 neutralization titer of simVRC07 and huVRC07 in the 842 
TZM-bl assay. Neutralization titers  (IC50) are shown as μg/mL of the indicated antibody and 843 
are color-coded as follows: <0.1 (red), 0.1-.99 (orange), 1-4.9 (yellow), 5-50 (green); >50 844 
(white). NA, fold change could not be calculated due to lack of neutralization by both 845 
antibodies.  846 
 847 
Figure 2. AAV8 delivery of simVRC07 genes confers systemic and mucosal expression 848 
in immunodeficient mice and immunocompetent rhesus macaques. (A) The vector 849 
transgene design for single stranded AAV8 vectors.  ITR, inverted terminal repeat; F2A, 850 
furin-2A sequence; pA, poly adenylation sequence. (B) Comparison of huVRC07 and 851 
simVRC07 serum concentrations in SCID mice after administration of 2.5×1010 vector 852 
genomes (vg) of AAV8 vectors. Values shown are mean ± SEM of three or six mice. (C) 853 
Plasma simVRC07 concentration in rhesus macaques administered 1×1013 vg of AAV8-854 
simVRC07. Values shown are mean ± SEM of triplicate independent measurements. (D) 855 
Immunoperoxidase staining for simVRC07 IgG in cross-sections of macaque rectal tissue by 856 
HIV envelope reverse immunohistochemistry.  Rectal biopsies were collected before and 3 857 
weeks after AAV8-simVRC07 administration and stained with a labeled RSC3 protein. 858 
Magnification is ×40 the original image. Images are representative of staining performed on 859 
macaques DBM8 and AZ36. 860 
 861 
Figure 3. Characterization of anti-simVRC07 humoral immunity in macaques.  (A) 862 
Time course of anti-simVRC07 antibodies measured by biolayer interferometry in the 863 
macaques administered 1×1013 vg of AAV8-simVRC07 in Fig. 2C.  Plasma immunoglobulin 864 
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binding to simVRC07 (solid lines) or control macaque IgG (dashed lines) are shown for each 865 
macaque.  Values shown are mean ± SEM of triplicate independent measurements.  (B) 866 
Spearman correlation between plasma simVRC07 concentration and the anti-simVRC07 867 
plasma antibody response quantified in A (Spearman r = -0.7819).  Symbols are coded to 868 
correspond to each rhesus macaque in A.  Anti-simVRC07 responses inversely correlated 869 
with detectable plasma simVRC07 concentration. (C) Blocking of simVRC07, huVRC07, 870 
or VRC03 binding to a HIV-1 gp120. Macaque plasma from before AAV8-simVRC07 871 
vector administration (Week 0) or 9 weeks after vector administration (Week 9) was 872 
tested for blocking of the monoclonal antibodies. Binding in the presence of no plasma 873 
served as the baseline binding control. The mean of triplicate measurements are shown. 874 
 875 
Figure 4. Cellular and humoral immune responses against the F2A peptide in macaques 876 
administered 1×1013 vg of AAV8-simVRC07.  (A, B) Intracellular cytokine staining of 877 
CD8+ T cells (A) and CD4+ T cells (B) stimulated with a pool of overlapping F2A peptides. 878 
The dotted line represents the previously determined threshold for positivity for each 879 
cytokine (37). Due to PBMCs availability T cell responses were analyzed 12 and 25 weeks 880 
post-administration for AZ36 and DBM8, and 5 and 7 weeks post-administration for AZ66 881 
and 2F7. (C) ELISA direct plasma IgG binding to pooled F2A peptides. The binding titer is 882 
represented as log10 area-under-the-curve (AUC) for the four macaques shown in A and B 883 
over time. 884 
 885 
Figure 5. Transient immune suppression during gene transfer increases peak 886 
simVRC07 concentration and duration of expression.  (A)  SimVRC07 plasma 887 
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concentration in five rhesus macaques treated with cyclosporine A (CsA) as indicated on the 888 
x-axis.  AAV8-simVRC07 was administered at week 0 (solid vertical line).  The time point 889 
for SHIV-BaLP4 challenge is shown as a dashed vertical line.  Values are the mean ± 890 
standard error for triplicate independent measurements. (B) Comparison of peak plasma 891 
simVRC07 concentration after AAV8-simVRC07 injection in the untreated macaques in Fig. 892 
2C or the macaques treated with CsA in A. The mean peak concentration for each group of 893 
animals is shown by the horizontal bar ± SEM. Significantly higher peak plasma 894 
concentrations were observed in macaques that received CsA compared to untreated 895 
macaques (Mann-Whitney, P=0.0095). (C) Biolayer interferometry binding of plasma 896 
immunoglobulin from the macaques shown in A. to macaque IgG (left) and simVRC07 IgG 897 
(right).  The duration of CsA treatment is indicated on the x-axis.  Mean values ± SEM of 898 
triplicate independent measurements are shown. 899 
 900 
Figure 6. SimVRC07 gene transfer protects against mucosal SHIV challenge.  (A) 901 
Plasma neutralization titers (ID50) against the SHIV-BaLP4 challenge stock on the day of 902 
challenge. The neutralization titer in the plasma for A11E035 was not determined (ND) since 903 
it did not have detectable simVRC07 in its plasma at this time point. ID50 is shown as 904 
reciprocal plasma dilution and is color-coded as follows: >500 (red), 300-500 (orange), 100-905 
299 (yellow), 10-99 (green); <10 (white). Murine leukemia virus (SVA-MLV) was analyzed 906 
as a negative control virus.  (B) Plasma viral loads of rhesus macaques administered AAV8 907 
vectors encoding control IgG (left), or simVRC07 (right) and challenged with SHIV-BaLP4 908 
5.5 weeks later. Prior to SHIV-BaLP4 challenge, both groups of animals received the same 909 
course of CsA treatment beginning 1 week before AAV8 administration and ending at week 910 
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4. Significantly more macaques were infected in the control group compared to the 911 
simVRC07 group (treatment group n = 6, control group n = 5; Fisher's Exact P= 0.0455).  912 
Table 1. AAV8 plasma neutralization titer (ID50) 
Animal ID Week 0 Week 3 
AZ36 <20 3994 
AZ66 <20 176 
DBM8 <20 4269 
2F-7 <20 303 
 






